Condition: Acute Ischemic Stroke · Sponsor: Xuanwu Hospital, Beijing
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.
This description comes directly from the study's public registry record.
Junwei Hao, MD; PhD · 010 8319 8277 · haojunwei@vip.163.com
Gaoting Ma, MD · 18301579891 · demo_doctor@163.com
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital, Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06138210